EMERYVILLE, Calif.–(BUSINESS WIRE)–Feb 4, 2021–
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the pricing of its upsized initial public offering of 9,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Lucira from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $153.0 million. In addition, Lucira has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock, at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “LHDX” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.
BofA Securities and William Blair are acting as lead bookrunning managers and LifeSci Capital is acting as co-manager for the offering.
The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained from: BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by email at dg.prospectus—[email protected], or William Blair, Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687 or email at [email protected].
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on February 4, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lucira Health
Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210204006199/en/
CONTACT: Media Relations
Kevin Knight
[email protected]
206-451-4823Investor Relations
Jeremy Feffer
[email protected]
212-915-2568
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY MEDICAL SUPPLIES GENERAL HEALTH HEALTH MEDICAL DEVICES INFECTIOUS DISEASES
SOURCE: Lucira Health, Inc.
Copyright Business Wire 2021.
PUB: 02/04/2021 11:27 PM/DISC: 02/04/2021 11:27 PM
http://www.businesswire.com/news/home/20210204006199/en
